Search
Silicon
go.drugbank.com/drugs/DB12982ApprovedSilicon is under investigation in clinical trial NCT00103246 (Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or
Mixtures: Calcium With Mg Zn Mn Cu CR Si and Vit. C & D, Calcium Complex High GradeMagnesium acetate tetrahydrate
go.drugbank.com/drugs/DB09409ApprovedWithdrawnMagnesium is an essential element and second most abundant cation in the body that plays a key role in maintaining normal cellular function such as production of ATP and efficient enzyme activity. … Magnesium acetate tetrahydrate can be used as an electrolyte supplementation or a reagent in molecular biology experiments.
Mixtures: Numeta G 13 % E Emulsion zur Infusion, Numeta G 16 % E Emulsion zur InfusionTrastuzumab
go.drugbank.com/drugs/DB00072ApprovedInvestigationalProduced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody [A40276] that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular … In Canada, biosimilars ONTRUZANT[[L40303, L40308] and Adheroza[L52835] are approved. In November 2023, trastuzumab was also approved by the EMA under the brand name Herwenda.[L49339]
Categories: Complex MixturesUpadacitinib
go.drugbank.com/drugs/DB15091ApprovedInvestigational[L10896] In December 2019, it was additionally approved by the European Commission and Health Canada.[L10899,L42540] Upadacitinib is marketed under the brand name RINVOQ for oral administration. … Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression.
Ranibizumab
go.drugbank.com/drugs/DB01270ApprovedInvestigational[A246399] Ranibizumab was initially approved by the FDA in 2006 [A2301] and by the European Commission (EC) in 2007.[L41429] It is marketed under the brand names LUCENTIS and SUSVIMO. … [L41399] In August 2022, other biosimilars CIMERLI, RAIVISIO, and RANOPTO were approved by the FDA, EC, and Health Canada respectively.[L42625,L43513,L49141]
Products: LUCENTIS 10 MG/ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE, LUCENTIS SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 1.65mg/0.165mlIndium In-111 chloride
go.drugbank.com/drugs/DB09490ApprovedIt is supplied as a sterile, pyrogen-free solution of Indium ("'In) Chloride in O.04M HCI. … and for radiolabeling Zevalin (ibritumomab tiuxetan) in preparations used for radioimmunotherapy procedures.
Synonyms: Indium chloride In-111, Indium In 111 chlorideMixtures: INDIO (111-IN) OSSINA CURIUM NETHERLANDS, Kit for the Preparation of Indium In 111 PentetreotideEcamsule
go.drugbank.com/drugs/DB09534ApprovedEcamsule has been approved for use in the U.S. since 2006, but only at a specific concentration and only in a few products manufactured by L'Oreal. … Ecamsule is an organic compound which is added to many sunscreens to filter out UVA rays. It is a benzylidene camphor derivative, many of which are known for their excellent photostability.
Mixtures: /enf., Anthelios XL Melt-IN CreamCategories: Compounds used in a research, industrial, or household settingTeplizumab
go.drugbank.com/drugs/DB06606ApprovedInvestigational[L44091] Fc-receptors can bind to the "tail-end" anti-CD3 antibodies in an antigen-non-specific manner and lead to severe adverse effects related to cytokine release syndrome (CRS). … Teplizumab was designed as an Fc-non-binding antibody in order to reduce the incidence of CRS.
Categories: Drugs Used in DiabetesSalmeterol
go.drugbank.com/drugs/DB00938ApprovedInvestigational[A190459] Salmeterol was first described in the literature in 1988.[A190477] Salmeterol's structure is similar to salbutamol's with an aralkyloxy-alkyl substitution on the amine. … [A183737] Salmeterol was granted FDA approval on 4 February 1994.[L11542]
Mixtures: SALFLUTIN 50/100UG 60 ED, SALFLUTIN 50/250UG 60 EDEfavirenz
go.drugbank.com/drugs/DB00625ApprovedInvestigationalEfavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with … For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen.
Mixtures: TENOLAM-E, EFAVIRENZ, EMTRICITABINA E TENOFOVIR DISOPROXIL EGCategories: Antivirals used in combination for the treatment of HIV infections